Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) has suffered a setback with one of its late-stage drugs. The company’s drug for treating a bleeding disorder failed to obtain statistical significance, in a second late-stage trial. As such, investors have been abandoning the stock, which continues to decline in the stock market. The main setback in the trial was when one of the patients in the placebo group, demonstrated a stable platelet response, which had not been evident in early-stage trials.

Trade ahead of the curve. This new Healthcare company is already working on treatments for the Zika Virus and just announced entry into the $35 Billion Analgesic Market. Read More

RIGL had been developing the drug as a treatment option for chronic immune thrombocytopenia, a condition where the immune system starts attacking the blood platelets of the body itself. The company noted that when the data from the two late-stage studies was combined, it hinted at a possible surge in platelet count, within weeks of treatment.

The trials did not demonstrate any unusual safety issues, but did demonstrate gastrointestinal related events. The CEO of RIGL, Raul Rodriguez, expressed his belief that the two trials combined demonstrate a clear treatment effect and a sustained clinical benefit of the drug. He stated that the company would continue developing the drug, after receiving feedback from the FDA.

In addition to this, the company recently granted rewards under its inducement plan, which had earlier been approved by Rigel’s compensation committee. As per the plan, the new CCO of RIGL, Eldon C. Mayer III was granted 300,000 stock options, whereas the new VP of Business Development and Alliance Management, Joseph Lasaga, was awarded 150,000 stock options. Another 40,000 stock options were awarded to an unnamed new employee. The options entitle the option holders to purchase Rigel’s common stock, at its share price, as of October 7, 2016, a day prior to the award. It should be noted here that Mr. Lasaga and Mr. Mayer would receive 50,000 and 100,000 additional stock options, upon completion of certain milestones.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) had a trade volume of 18.25 million and lost 15.22% of its share value, during the October 20 trading session, to close at $2.73 per share.

Previous articleDragonWave, Inc. (USA) (NASDAQ:DRWI) To Provide Microwave Backhaul Equipment To Sprint
Next articleOrganovo Holdings Inc (NASDAQ:ONVO) Improves Cash Position and Updates FY2017 Guidance
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg,,, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.